Full Text

Turn on search term navigation

© 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The colon is the largest compartment of the immune system, with innate immune cells exposed to antigens in the environment. However, the mechanisms by which the innate immune system is instigated are poorly defined in colorectal cancer (CRC). Here, a population of CD16+ neutrophils that specifically accumulate in CRC tumor tissues by imaging mass cytometry (IMC), immune fluorescence, and flow cytometry, which demonstrated pro-tumor activity by disturbing natural killer (NK) cells are identified. It is found that these CD16+ neutrophils possess abnormal cholesterol accumulation due to activation of the CD16/TAK1/NF-κB axis, which upregulates scavenger receptors for cholesterol intake including CD36 and LRP1. Consequently, these region-specific CD16+ neutrophils not only competitively inhibit cholesterol intake of NK cells, which interrupts NK lipid raft formation and blocks their antitumor signaling but also release neutrophil extracellular traps (NETs) to induce the death of NK cells. Furthermore, CD16-knockout reverses the pro-tumor activity of neutrophils and restored NK cell cytotoxicity. Collectively, the findings suggest that CRC region-specific CD16+ neutrophils can be a diagnostic marker and potential therapeutic target for CRC.

Details

Title
Region-Specific CD16+ Neutrophils Promote Colorectal Cancer Progression by Inhibiting Natural Killer Cells
Author
Zhang, Yan 1   VIAFID ORCID Logo  ; Wang, Zien 1 ; Lu, Yu 2 ; Sanchez, David J 3 ; Li, Jiaojiao 4 ; Wang, Linghao 5 ; Meng, Xiaoxue 5 ; Chen, Jianjun 6 ; Tran, Trung Kien 7 ; Zhong, Ming 6 ; Wei-Qiang, Gao 1   VIAFID ORCID Logo  ; Ding, Xianting 8   VIAFID ORCID Logo 

 State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China; Med-X Research Institute & School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China 
 State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China 
 Pharmaceutical Sciences Department, College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA 
 School of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Sydney, NSW, Australia 
 Med-X Research Institute & School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China 
 Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China 
 Oncology department, University Medical Shing Mark Hospital, Dong Nai, Vietnam 
 State Key Laboratory of Oncogenes and Related Genes, Institute for Personalized Medicine, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China 
Section
Research Article
Publication year
2024
Publication date
Aug 2024
Publisher
John Wiley & Sons, Inc.
e-ISSN
21983844
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3089810428
Copyright
© 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.